MA-MARIANA-ONCO/NOVARTIS
2.5.2024 13:01:28 CEST | Business Wire | Press release
Mariana Oncology, a fully integrated biotechnology company pioneering a new era of radiopharmaceutical innovation to treat people with cancer, today announced it will be acquired by Novartis for $1 billion upfront and up to $750 million in potential milestone payments. The acquisition brings together Mariana Oncology’s innovative radiopharmaceutical pipeline and platform with the proven clinical development and commercialization expertise of Novartis.
Mariana Oncology has developed a robust portfolio of novel peptide based-radiopharmaceuticals targeting a broad spectrum of solid tumor cancers, and has invested in manufacturing capabilities, an extensive isotope supply chain and novel formulations to enhance final product shelf-life. The company’s lead program, MC-339, is a novel radioligand therapy (RLT) designed to target small cell lung cancer.
“Novartis is an established leader in the commercialization of radiopharmaceuticals with a world-class team and global reach. Together, we offer a compelling combination of capabilities,” said Simon Read, Founder and CEO, Mariana Oncology. “In the short time since founding the company, the team at Mariana Oncology has developed a leading radiopharmaceutical discovery platform and an innovative pipeline. Our strategy has centered on overcoming the unique challenges of end-to-end radiopharmaceutical R&D and ultimately, delivery of these drugs to the bedside. Both Mariana and Novartis are committed to transforming cancer care, and together we will be in a better position to do that.”
“This acquisition of Mariana Oncology brings to Novartis phenomenal talent and new capabilities in radioligand therapeutic research that complement our wide-ranging internal research and drug discovery efforts, in addition to our translational and clinical development capabilities,” said Shiva Malek, PhD, Global Head of Oncology for Biomedical Research at Novartis. “This is an ideal pairing, and we are thrilled to continue to do pioneering science together, translating RLT discovery into clinical development to deliver transformative therapies to patients.”
Mariana was founded in 2021 by Atlas Venture, Access Biotechnology and RA Capital Management, and has raised additional funds from other top investors including DeepTrack Capital and Forbion.
The transaction is subject to customary closing conditions.
Centerview Partners LLC served as financial advisor, and Goodwin Procter as legal counsel to Mariana Oncology on the transaction.
About Mariana Oncology
Mariana Oncology is a fully integrated, radiopharmaceutical company pioneering a new standard of care in cancer treatment – targeted peptide-based radioligand therapeutics (RLTs) designed to maximize tumor penetration while minimizing toxicity. Mariana is comprised of some of the world’s leading experts in radiopharmaceutical science and manufacturing who together are pioneering innovations in end-to-end discovery, development and delivery of radioligand therapeutics. The company has developed a portfolio of novel RLTs designed to target a broad range of difficult-to-treat cancers. Mariana’s lead program, MC-339, is an actinium-based radioligand therapeutic being investigated to treat small cell lung cancer.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240502315526/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Visa Expands Commercial Solutions Hub with Integration of Visa Accounts Receivable Manager27.5.2026 14:00:00 CEST | Press release
New integration allows issuers to send virtual card details to suppliers, helping automate virtual card adoption for suppliers at scale Visa Inc. (NYSE: V), a global leader in digital payments, today announced an expansion of the Visa Commercial Solutions Hub (VCS Hub), further strengthening how issuers and suppliers connect to scale virtual card programs. Through a new integration with Visa Accounts Receivable Manager (Visa AR Manager), eligible issuers gain built-in access to end-to-end processing designed to reduce operational friction and accelerate commercial card growth. Virtual cards are among the fastest-growing payment methods in commercial payments yet scaling them remains complex. Issuers often face fragmented supplier connectivity, while suppliers are left with manual reconciliation and inconsistent payment flows. By bringing issuer and supplier networks together, by embedding access to Visa AR Manager in the VCS Hub, Visa is helping to simplify these connections and enable
Parse Biosciences and bit.bio Announce Landmark Alliance27.5.2026 14:00:00 CEST | Press release
Unlocking Cell Fate: Alliance will power AI-driven predictive medicine and human cell manufacturing Parse Biosciences, the leading provider of scalable and accessible single cell sequencing solutions, today announced an alliance with bit.bio to create a comprehensive map of transcription factor-driven cell identity, encompassing both cell state and cell fate. This map will serve as the foundational blueprint for developing highly accurate, human-relevant models at scale. By precisely mimicking in vivo biological responses, these models will significantly advance predictive drug discovery and therapeutic development. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260527668821/en/ The alliance will leverage cutting-edge techniques in massively parallel causal transcriptomics, which allows scientists to test thousands of genetic variables simultaneously to understand what drives cell behavior. bit.bio will contribute its indust
Echodyne Expands Public Safety Radar Applications Through Partnership with Axon27.5.2026 14:00:00 CEST | Press release
Partnership supports safer and more scalable drone operations across law enforcement, homeland security, and Drone as First Responder programs globally Echodyne, the radar platform company, today announced a partnership with Axon (Nasdaq: AXON), the global public safety technology leader, to support a joint focus activity on delivering best in class infrastructure for a range of homeland security and law enforcement UAS applications in the U.S and globally. Under the partnership, Echodyne’s advanced radar technology will continue supporting Axon’s growing ecosystem of public safety drone solutions, enhancing low-altitude airspace awareness for authorized drone operations while helping agencies detect and respond to unauthorized or malicious drone activity. There is increasing demand globally for comprehensive detailed awareness of the low altitude airspace in which drones are proliferating. Drone as First Responder (DFR) operations can deliver critical information to public safety agen
ENGIE and NHOA Energy Break Ground on 320MWh Drogenbos Battery Project in Belgium27.5.2026 13:22:00 CEST | Press release
Construction officially underway, marking a key milestone in the delivery of one of the largest battery storage systems in Benelux NHOA Energy, global provider of utility-scale energy storage systems, joined ENGIE today in marking a significant milestone with the groundbreaking ceremony of a 320MWh Battery Energy Storage System (BESS) at ENGIE’s Drogenbos power station, near Brussels. The ceremony, held this morning in the presence of Hans Bonte, Minister of Energy of the Government of Flanders, Vincent Verbeke, CEO of ENGIE Belgium, Nicolas van den Abeele, Managing Director Renewables & Batteries Benelux of ENGIE, and Giuseppe Artizzu, CEO of NHOA Energy, marked the official start of construction of ENGIE’s third large-scale battery project in Belgium. Awarded under Belgium’s fifth Capacity Remuneration Mechanism (CRM) auction, the project will contribute to the adequacy of the national electricity system under a 15-year contract starting in November 2027. ENGIE has entrusted NHOA Ene
NIQ Launches Survey Groups to Connect Consumer Sentiment with Real Purchase Behavior27.5.2026 13:00:00 CEST | Press release
New integrated capability connects consumer sentiment with real-world purchase data, enabling more confident, action‑driven decisions NIQ (NYSE: NIQ), a global leader in consumer intelligence, today announced the launch of Survey Groups in NIQ Discover, a new capability that enables brands and retailers to understand not just what is changing in the market, but why. Available immediately within NIQ Discover, Survey Groups build on NIQ Panel Surveys by linking attitudinal insights to real-world purchase behavior from NIQ’s consumer panels—helping clients uncover the motivations behind performance shifts, identify opportunity gaps, and act with greater confidence in an increasingly complex consumer landscape. What’s New: Survey Groups in Discover Survey Groups make NIQ Panel Survey insights easier to access, analyze, and activate within existing workflows. By grouping survey responses with purchase behavior, clients can: Analyze key consumer segments with greater precision Understand the
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom